Patients with acute myeloid leukemia are extremely susceptible to infection, especially due to the prevalence of neutropenia.
Patients with acute myeloid leukemia (AML) are extremely susceptible to infection, especially due to the prevalence of neutropenia. This condition is the primary risk factor of infection for this patient population, Yoav Golan, MD, MS, FIDSA, attending physician and associate professor of medicine at Tufts University School of Medicine, told MD Magazine as part of a recent Peer Exchange.
Neutropenia is typically defined as an absolute neutrophil count (ANC) count of less than 1500; real neutropenia is less than 1000; and severe neutropenia is less than 500. Patients with a count of lower than 100 are considered to be at the highest risk of infection.
There are several contributing causes to the high rate of neutropenia within AML patients.
“One of the causes of neutropenia is, in fact, the disease itself,” Dr Golan explained. “The expansion of one clone of white cells will prevent other white cells from flourishing and the diversity of those neutrophils—not necessarily their number—would be reduced. The expansion of this clone in the bone marrow will prevent the production of new neutrophils and will result in neutropenia as well.”
Other factors involve AML treatments which target the immune system and exacerbate a patient’s immunocompromised state. Additionally, chemotherapy treatments further deplete the number of neutrophils and are the main reason for neutropenia during AML therapy.
Besides neutropenia and a weakened immune system, patients may also contract infections from minor exposures such as raw foods, well water, and interactions with some pets—for example, patients should avoid cleaning cat litter. Other high risk exposures come from increased time in the healthcare system where procedures and lines interrupt mucosal surfaces.
Preventive measures include avoiding unnecessary risks, patient vaccinations and vaccinations for those in consistent contact with the patient, infection control actions such as thorough hand hygiene or wearing masks during intense treatment periods, and antimicrobial prophylaxis.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More